Could Helicobacter pylori treatment reduce stomach cancer risk?;Faut-il éradiquer Helicobacter pylori pour prévenir cancer gastrique?

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 3 II, 2003, Pages 440-452

  Bretagne, Jean François ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; SODIUM CHLORIDE;

BACTERIAL INFECTION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIETARY INTAKE; ENVIRONMENTAL FACTOR; ERADICATION THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER PYLORI; HOST; HUMAN; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SALT INTAKE; SMOKING HABIT; STOMACH CARCINOMA; STOMACH LYMPHOMA;

ADENOCARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DIET; ENDOSCOPY, GASTROINTESTINAL; EPIDEMIOLOGIC STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; PRECANCEROUS CONDITIONS; PUBLIC HEALTH; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0037365389     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. World Health Organization. Infection with Helicobacter pylori: Shistosomes, liver flukes, and Helicobacter pylori. In: IARC Monographs on the Evaluation of Carcinogenic Risks to the Humans. 1994;61:177-240.
2. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: cancer incidence, mortality and prevalence worldwide. CD-Rom, IARC Press 2001.
3. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol. 2002;12:111-27.
4. Benhamiche AM, Colonna M, Aptel I, Launoy G, Schaffer P, Arveux P et al. Estimation de l'incidence des cancers du tube digestif par région. Gastroenterol Clin Biol 1999;23:1040-7.
5. Bouvier AM, Estève J, Mitry E, Clinard, Bonithon-Kopp C, Faivre J. Trends in gastric cancer incidence in a well-defined French population by time period and birth cohort. Submitted for publication.
6. Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002;97:811-8.
7. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
8. Arsène D, Chomontowski J, Pottier D, Rougereau A, Launoy G, Gignoux M. Epidémiologíe et pronostic des carcinomes gastriques dans le département du Calvados. Etude sur 10 ans. Gastroenterol Clin Biol 1995;19:797-803.
9. Le Page M, Cauvin JM, Le Dréau G, Nousbaum JB, Enard L, Gourlaouen A et al. Prise en charge thérapeutique et survie de l'adénocarcinome gastrique dans le département du Finistère entre 1984 et 1989. Gastroenterol Clin Biol 1995;19:804-10.
10. Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1988-1997: the fall may approach 80,000 deaths a year. Int J Cancer 2002;98:636-7.
11. Haruma K. Trend toward a reduced prevalence of Helicobacter pylori infection, chronic gastritis, and gastric cancer in Japan. Gastroenterol Clin North Am 2000;29:623-31.
12. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N et al. Association between infection with Helicobacter pylori and risk of gastric cancer. Evidence from a prospective investigation. BMJ 1991;302:1302-5.
13. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perz-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaï. N Engl J Med 1991;325:1132-6.
14. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
15. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
16. Eslick GD, Lim LL, Chen Y, Hunt RH. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-9.
17. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 control studies nested within prospective cohorts. Gut 2001;49:347-53.
18. Ekström AM, Held M, Hansson LE, Engstrand L, Nyrén O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001;121:784-91.
19. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
20. The Eurohepygast Study Group. Epidemiology of, and risk factors for Helicobacter pylori infection among 3,194 asymplomatic subjects in 17 populations. Gut 1993;34:1672-6.
21. Holcombe C. Helicobacter pylori: the African enigma. Gut 1992;33:429-33.
22. Miwa H, Go MF, Sato NS. H. pylori and gastric cancer: the Asian enigma. Am J Gastroenterol 2002;97:1106-12.
23. Kuipers EJ, Perez-Perez GI, Meuwissen SGM, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of CagA status. J Natl Cancer Inst 1995;87:1777-80.
24. The Eurohepygast Study Group. Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. Gut 2002;50:779-85.
25. Kikuchi S, Crabtree JE, Forman D, Kurosawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Am J Gastroenterol 1999;94:3455-9.
26. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998;42:338-43.
27. Nomura A, Lee J, Stemmerman GN, Nomura RY, Perez-Perez GI, Blaser MJ. Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis 2002;186:1138-44.
28. Basso D, Navaglia F, Brigato L, Piva MG, Toma A, Greco E et al. Analysis of vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. Gut 1998;43:182-6.
29. Miehlke S, Kirsch C, Agha-Amiri K, Gunther T, Lehn N, Malfertheiner P et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000;87:322-7.
30. Rugge M, Busatto G, Cassaro M, Shiao YH, Russo V, Leandro V et al. Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer 1999;85:2506-11.
31. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W et al. Clinical relevance of the cagA, ratA, and iceA status of Helicobacter pylori. Gastroenterology 1999;115:58-66.
32. Hsu PI, Hwang I, Cittelly D, Lai KH, El-Zimaity HMT, Gutierrez O et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 2002;97:2231-8.
33. Fischer W, Püls J, Buhrdorf R, Gebert B, Odenbreit S, Haas R. Systematic mutagenesis of the Helicobacter pylori pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8. Mol Microbiol 2001;42:1337-48.
34. van Doorn LJ, Figueiredo C, Mégraud F, Pena S, Midolo P, Queiroz DM et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999;116:823-30.
35. Figueiredo C, van Doorn LJ, Nogueira C, Soares JM, Pinho C, Figueira P et al. Helicobacter pylori genotypes are associated with clinical outcome in Portuguese patients and show a high prevalence of infections with multiple strains. Scand J Gastroenterol 2001;36:128-35.
36. Shimoyama T, Yoshimura T, Mikami T, Fukuda S, Crabtree JE, Munakata A. Evaluation of Helicobacter pylori vacA genotype in Japanese patients with gastric cancer. J Clin Pathol 1998;51:299-301.
37. Mukhopadhyay A, Kersulyte D, Jeong J, Datta S, Ito Y, Chowdhury A et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol 2000;182:3219-27.
38. Kidd M, Peek RM, Lastovica AJ, Israel DA, Kummer AF, Louw JA. Analysis of iceA genotypes in South African Helicobacter pylori strains and relationship to clinically significant disease. Gut 2001;49:629-35.
39. Broutet N, Moran A, Hynes S, Sakarovitch C, Mégraud F for The Eurohepygast Group. Lewis antigen expression and other pathogenic factors in the presence of atrophic chronic gastritis in a European population. J Infect Dis 2002;185:503-12.
40. Nogueira C, Figueiredo C, Carneiro F, Gomes AT, Barreira R, Figueira P et al. Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001;158:647-54.
41. Yu J, Leung WK, Go MYY, Chan MCW, To KF, Ng NKW et al. Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut 2002;51:480-4.
42. Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci 1999;96:127778-83.
43. Haas G, Karaali G, Ebermayer K, Metzger WG, Lamer S, Zimny-Arndt U et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2002;2:313-24.
44. Suganuma M, Kurusu M, Okabe S, Sueoka N, Yoshida M, Wakatsuki Y et al. Helicobacter pylori membrane protein 1: a new carcinogenic factor of Helicobacter pylori. Cancer Res 2001;61:6356-9.
45. Israel DA, Peek RM. Pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 2001;15:1271-90.
46. Lamarque D, Tran-Van Nhieu J, Bréban M, Delchier JC. La réponse inflammatoire gastrique dans l'infection par Helicobacter pylori. Gastroenterol Clin Biol 2002;26:162-70.
47. Mattapallil JJ, Dandekar S, Canfield DR, Solnick JV. A predominant Th1 type of immune response is induced early during acute Helicobacter pylori infection in Rhesus macaques. Gastroenterology 2000;118:307-15.
48. El-Omar EM. The importance of interleukin 1β in Helicobacter pylori associated disease. Gut 2001;48:743-7.
49. El-Omar EM, Carrington M, Chow WH, McColl KEL, Bream JH, Young HA et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
50. El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000;118:22-30.
51. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C et al. Interleukin 1B and interleukin IRN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-9.
52. Furata T, Shirai N, Takashima M, Xiao F, Sugimura H. Effect of genotypic differences in interleukin 1β on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am J Med 2002;112:141-3.
53. Furata T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H, Interleukin 1β polymorphisms increase risk of hypochlorhdria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002;123:92-105.
54. Hansson LE, Nyrén O, Hsing AW, Bergström R, Josefsson S, Chow WH et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.
55. El-Omar EM, Chow WH, Gammon MD, Vaughan TL, Risch HA, Fraumeni JF Jr. Pro-inflammatory genotype IL-1β, TNF-α and IL-10 increase risk of distal gastric cancer but not of cardia or esophageal adenocarcinomas (abstract). Gastroenterology 2001;120:A86.
56. El-Omar EM, You WC, Chow WH, Fraumeni JF Jr, Rabkin CS. IL1β and IL-10 genotypes in a high gastric cancer risk province in China (abstract). Gastroenterology 2001;120:A743.
57. Chiba T, Watanabe T, Ito T. Helicobacter pylori infection and acid secretion in patients with duodenal ulcer in Japan. Gut 2001;48:871-2.
58. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori-independent chronological change in gastric acid secretion in the Japanese. Gut 1997;41:452-8.
59. Roe I, Nam S, Kim J, Shin J, Bang W, Yang M. Association of the myeloperoxidase -463 G/A polymorphism with development of atrophy in Helicobacter pylori infected-gastritis. Am J Gastroenterol 2002;97:1629-34.
60. Rigas B. HLA and disease association: the case of gastric cancer. Gastroenterology 1996;111:523-6.
61. Lee JE, Lowy AM, Thompson WA, Lu M, Loflin PT, Skibber JM et al. Association of gastric adenocarcinoma with the HLA class II gene DQB1*0301. Gastroenterology 1996;111:426-32.
62. Magnusson PKE, Enroth H, Eriksson I, Held M, Nyrén O, Engstrand L et al. Gastric cancer and human leucocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res 2001;61:2684-9.
63. Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y et al. The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer 1998;82:1013-8.
64. Ohtani M, Azuma T, Murramatsu A, Saito T, Suto H, Dojo M et al. Association of HLA-DRB1 gene locus with Helicobacter pylori infection in patients with atrophic gastritis or gastric adenocarcinoma in Japan (abstract). Gut 2002;51:A55.
65. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Nat Cancer Inst 2002;94:1680-7.
66. Yamaguchi N, Kakizoe T. Synergistic interaction between Helicobacter pylori gastritis and diet in gastric cancer. Lancet Oncol 2001;2:84-94.
67. Forman D. Is there significant variation in the risk of gastric cancer associated with Helicobacter pylori infection? Aliment Pharmacol Ther 1998;12:3-7.
68. Brenner H, Arndt V, Bode G, Stegmaier C, Ziegler H, Stumer T. Risk of gastric cancer among smokers infected with Helicobacter pylori. Int J Cancer 2002;98:446-9.
69. Siman JH, Forsgren A, Berglund G, Floren CH. Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001;36:208-13.
70. Serafini M, Bellocco R, Wolk A, Ekström AM. Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 2002;123:985-91.
71. Kobayashi M, Tsubono Y, Sasazuki S, Sasaki S, Tsugane S, for the JPHC Study Group. Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC study cohort I. Int J Cancer 2002;102:39-44.
72. Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
73. Varis K, Taylor R, Sipponen P, Samloff M, Heinonen OP, Albanes D et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. Scand J Gastroenterol 1998;33:294-300.
74. Malila N, Taylor PR, Virtanen MJ, Korhonen P, Huttunen JK, Albanes D et al. Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers. Cancer Causes Control 2002;13:617-23.
75. Watanabe T, Tada M, Nagai H, Saski S, Nakao M. Helicobacter pylori infection; induces gastric cancer in Mongolian gerbils. Gastroenterology 1998;115:642-8.
76. Sugiyama A, Maruta F, Ikeno T, Ishida K, Kawasaki S, Katsuyama T et al. Helicobacter pylori infection enhances N-methyl-N-nitrososurea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998;58:2067-9.
77. Tokieda M, Honda S, Fujioka T, Nasu M. Effect of Helicobacter pylori infection on the N-methyl-N'-nitrosoguanidine-induced gastric carcinogenesis in Mongolian gerbils. Carcinogenesis 1999;20:1261-6.
78. Takashima M, Furuta T, Hanai H, Sugimura H, Kaneko E. Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 2001;48:765-73.
79. Ogura K, Maeda S, Watanabe T, Tada M, Kyutoku T, Yoshida H et al. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbils. J Exp Med 2000;192:1601-10.
80. Shimizu N, Ikehara Y, Inada KI, Nakanishi H, Tsukamoto T, Nozaki K et al. Eradication diminishes enhancing effects of Helicobacter pylori-infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000;60:1512-4.
81. Keto Y, Ebata M, Okabe S. Gastric mucosal changes induced by longterm infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication. J Physiol 2001;95:429-36.
82. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431-8.
83. Arista-Nasr J, Jiménez-Rosas F, Uribe-Uribe N, Herrera- Goepfert R, Lazos-Ochoa M. Pathological disorders of the gastric mucosa surrounding carcinomas and primary lymphomas. Am J Gastroenterol 2001;96:1746-50.
84. Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M. Atrophymetaplasia-dysplasia-carcinoma sequence in the stomach:a reality or merely an hypothesis? Best Pract Res Clin Gastroenterol 2001;15:983-98.
85. Sipponen P, Marshall BJ. Gastritis and gastric cancer. Western countries. Gastroenterol Clin N Am 2000;29:579-92.
86. El-Zimaity HMT, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002;94:1428-36.
87. Faraji EI, Frank BB. Multifocal atrophic gastritis and gastric carcinoma. Gastroenterol Clin N Am 2002;31:499-516.
88. Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol 2002;55:770-3.
89. Solcia E, Fiocca R, Luinetti O, Villani L, Padovan L, Calistri D et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol 1996;20:S8-S22.
90. Wambura C, Aoyama N, Shirazaka D, Sakai T, Ikemura T, Sakashita M et al. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 2002;7:129-38.
91. Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol 2001;96:16-26.
92. Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin N Am 2002;31:517-35.
93. Ebert MPA, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer: implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002;16:1059-66.
94. Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 2002;17:323-9.
95. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002;12:128-40.
96. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000;156:537-43.
97. Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I et al. Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci 2002;47:107-13.
98. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR et al. E-cadherin gene mutations provide clues to diffuse-type gastric carcinomas. Cancer Res 1994;54:3845-52.
99. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM et al. Ecaherin gene promoter hypermethylation in primary human gastric carcinomas. J Nat Cancer Inst 2000;92:569-73.
100. Chan JKC, Wong CSC. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 2001;8:165-72.
101. Shun CT, Wu MS, Lin MT, Chang MC, Lin JT, Chuang SM. Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and Helicobacter pylori infection. Oncology 2001;60:339-45.
102. Ebert MPA, Fei G, Kahmann S, Müller O, Yu J, Sung JY et al. Increased β-catenin mRNA levels and mutational alterations of the APC and β-catenin gene are present in intestinal type gastric cancer. Carcinogenesis 2002;23:87-91.
103. Wu MS, Shun CT, Wang HP, Sheu JC, Lee WJ, Wang TH, Lin JT. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997;112:1457-65.
104. Wu CW, Chen GD, Fann CSJ, Lee AFY, Chi CW, Liu JM et al. Clinical implications of chromosomal abnormalities in gastric adenocarcinomas. Gene Chrom Cancer 2002;35:219-31.
105. Carvalho R, Kayademir T, Soares P, Canedo P, Sousa S, Oliveira C et al. Loss of heterozygoty and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest 2002;82:1319-26.
106. Leung WK, Yu J, Chan FKL, To KF, Chan MWY, Ebert MPA et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 2002;197:582-8.
107. Touati E, Michel V, Thiberge JM, Huerre M, Wuscher N, Labigne A. Infections par Helicobacter pylori et effets mutagènes chez la souris (abstract). Gastroenterol Clin Biol 2002;26:A110.
108. Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002;123:542-53.
109. Danesh J. Helicobacter pylori and gastric cancer: time for megatrials. Br J Cancer 1999;80:927-9.
110. Kakizoe T. Obstacles and their overcome in clinical intervention trial in Japan. Jpn J Cancer Res 2000;91:50.
111. Hamajima N, Matuo K, Watanabe Y, Suzuki T, Nakamura T, Matsuura A et al. A pilot study to evaluate stomach cancer risk reduction by Helicobacter pylori eradication. Am J Gastroenterol 2002;97:764-5.
112. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
113. Farinati F, Foschia F, Di Mario F, Cassaro M, Rugge M. H. pylori eradication and gastric precancerous lesions. Gastroenterology 1998;115:512-4.
114. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236-40.
115. Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology 1999;46:2048-56.
116. Nardone G, Staibano S, Rocco A, Mezza E, D'Armineto FP, Insabato L et al. Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. Gut 1999;44:789-99.
117. Sung JJY, Lin SR, Ching JYL, Zhou LY, To KF, Wang RT et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14.
118. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
119. Ruiz B, Garay J, Correa P, Fontham ETH, Bravo JC, Bravo LE et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281-7.
120. van Grieken NCT, Meijer GA, Weiss MM, Bloemena E, Lindeman J, Baak JPA et al. Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. Am J Gastroenterol 2001;96:2882-6.
121. Kokkola A, Sipponen P, Rahtelin H, Härkönen M, Kosunen TU, Haapiainen R et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002;16:515-20.
122. Annibale B, Di Giulio E, Caruana P, Lahner E, Capurso E, Bordi C et al. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther 2002;16:1723-31.
123. Staibano S, Rocco A, Mezza E, De Rosa G, Budillon G, Nardone G. Diagnosis of chronic gastritis by morphometric image analysis. A new method to overcome the confounding effect of the inflammatory infiltrate. J Pathol 2002;198:47-54.
124. Sugiyama T, Sasaki N, Kozawa H, Sato R, Fujioka T, Satoh K et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002;16:187-90.
125. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
126. Annibale B, Aprile MR, D'Ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients docs not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther. 2000;14:625-34.
127. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16:1923-32.
128. Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 2001;49:2-4.
129. Genta RM. A year in the life of the gastric mucosa. Gastroenterology 2000;119:252-4.
130. El-Zimaity HMT, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. Gut 2001;54:679-83.
131. Leung WK, Sung JJY. Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002;16:1209-16.
132. Yu J, Leung WK, Ng EKW, To KF, Ebert MPA, Go MYY et al. Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther 2001;15:1505-11.
133. Morgner A, Miehlke S, Stolte M, Neubauer A, Alpen B, Thieede C et al. Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J Gastroenterol 2001;7:248-53.
134. Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer 2002;5:6-15.
135. Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombe W et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled study. Aliment Pharmacol Ther 2002;16:559-68.
136. Fendrick AM. The role of economic evaluation in the diagnosis and treatment of Helicobacter pylori infection. Gastroenterol Clin N Am 2000;29:837-51.
137. Varis K, Sipponen P, Laxén F, Samloff IM, Huttunen JK, Taylor PR et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dyspepsia. Scand J Gastroenterol 2000;35:950-6.
138. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT. Fielding JWL. The long term results of endoscopic surveillance of premaligant gastric lesions. Gut 2002;50:378-81.
139. Jenks PJ, Mégraud F, Labigue A. Clinical outcome after infection with Helicobacter pylori does not appear to be reliably predicted by the presence of any of the genes of the cag pathogenecity island. Gut 1998;43:752-8.
140. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G. Individual and joint contribution of family history and Helicobacter pylory infection to the risk of gastric carcinoma. Cancer 2000;88:274-9.
141. Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.
142. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.
143. Conférence de consensus Helicobacter pylori. Révision 1999. Conclusions et recommandations révisées du groupe de travail. Gastroenterol Clin Biol 1999;23:C95-104.